Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-044335
Filing Date
2025-05-15
Accepted
2025-05-15 16:57:27
Documents
80
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0241691-10q_cero.htm   iXBRL 10-Q 1129040
2 CERTIFICATION ea024169101ex31-1_cero.htm EX-31.1 12194
3 CERTIFICATION ea024169101ex31-2_cero.htm EX-31.2 12152
4 CERTIFICATION ea024169101ex32-1_cero.htm EX-32.1 4861
5 CERTIFICATION ea024169101ex32-2_cero.htm EX-32.2 4876
  Complete submission text file 0001213900-25-044335.txt   7255780

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cero-20250331.xsd EX-101.SCH 73185
7 XBRL CALCULATION FILE cero-20250331_cal.xml EX-101.CAL 37500
8 XBRL DEFINITION FILE cero-20250331_def.xml EX-101.DEF 372692
9 XBRL LABEL FILE cero-20250331_lab.xml EX-101.LAB 611234
10 XBRL PRESENTATION FILE cero-20250331_pre.xml EX-101.PRE 385088
83 EXTRACTED XBRL INSTANCE DOCUMENT ea0241691-10q_cero_htm.xml XML 832684
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40877 | Film No.: 25955022
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)